|
|
drugsandteenagers
INTRON A (Interferon alfa-2b, recombinant) for Injection is contraindicated in patients with hypersensitivity to INTRON A or any component of the product, autoimmune home testing kits hepatitis, and decompensated liver cancer. Contraindications PEGINTRON is contraindicated in patients with hypersensitivity to PEGINTRON or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before or during treatment. Per protocol, if a patient does not have a 24-week post-treatment assessment, the patient's 12-week home testing kits post-treatment assessment will be utilized. No increase in skin adverse events (rash or pruritus) was observed in the boceprevir arms beyond what was seen in the PEGINTRON and REBETOL control arm. And international sites. SVR, the protocol specified primary efficacy endpoint, is defined as achievement of undetectable HCV-RNA at 24 weeks after drug abuse detection the end of treatment.
These results compared to a 38 percent SVR rate (SVR 12) for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(2-4) Importantly, predictability of attaining SVR 12 or 24 based on rapid virologic response (RVR) was greater for boceprevir patients in the lead-in arms compared to the no lead-in azure. Interim Results from the HCV SPRINT-1 Study. If patients develop psychiatric problems, including clinical depression, it is supported that patients be carefully monitored sperm count tests during treatment and in the 6-month follow-up period.
Physicians and patients are encouraged to report such cases by calling 1-800-593-2214. In addition, the patient's immune system will have been activated and primed by PEGINTRON at the time that boceprevir is added to the regimen. The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha.
The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. PEGINTRON or INTRON A in combination with REBETOL therapy is additionally contraindicated in patients with hypersensitivity to ribavirin or any hiv test other component of the product, women who are pregnant, men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL/min. About Hepatitis C Hepatitis C is a serious and potentially life-threatening disease.
Labeling for PEGINTRON and REBETOL Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or aggravate dna test kits fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Avoid Pregnancy REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. SCHERING-PLOUGH DISCLOSURE NOTICE. Please see important full U.S. Schering-Plough does not assume the obligation to update any forward-looking statement. Safety data from the study sho that the most com adverse events reported in the boceprevir arms were fatigue, anemia, hiv testing kit nausea and headache. 4 weeks of PEGINTRON (1.5 mcg/kg once special) and REBETOL (800-1400 mg daily based on patient weight) therapy follo by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of the study, boceprevir in combination with PEGINTRON preventing substance abuse hiv home testing kit and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks, compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen).
Ribavirin may cause birth defects and/or death of the unborn child. This approach may minimize the period of time when there is a "functional monotherapy" with a direct antiviral, potentially reducing the likelihood for the development of resistance. most abused drugs pregnancy Aggressive behavior testing kits sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. In the PEGINTRON/REBETOL combination trial, the incidence of serious paternity tests adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL body. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or in an instant after completing treatment with dna home test kits PEGINTRON. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups.
Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient home test kits deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots. This is an ongoing study and SVR 24 rates are not yet available for patients in the 48-week boceprevir arms or the 48-week control arm of the study. Overall, 77 percent of the 595 patients in the study were enrolled in the United States. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, hiv testing kit including PEGINTRON and INTRON A. One study is in treatment-naive patients and the other in patients who failed prior treatment (relapsers and nonresponders).
Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Incidence of Adverse Events There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection home paternity tests site reactions, fever, rigors, nausea) were higher. The two randomized, double-blind, placebo-controlled studies evaluate the vehemence of boceprevir in combination with PEGINTRON and REBETOL compared to standard of care with PEGINTRON and REBETOL alone. The company is based in Kenilworth, N.J., and its Web site is /. If psychiatric symptoms persist or worsen, or suicidal ideation dna testing kits or aggressive behavior towards others is identified, it is recommended that morceau with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully follo with psychiatric intervention, as appropriate.
Depression was most com at 29%. The majority of these cases were mild and responded to dose reductions. Treatment discontinuations for boceprevir patients due to viral breakthrough were fewer in the 28- and 48-week lead-in home dna kit arms (4 and 5 percent, respectively) compared to the no lead-in arms (7 and 11 percent, respectively). Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around preventing substance abuse the world. It is the leading cause of cirrhosis and liver cancer, and the number one reason for inwards transplants in the United States and Europe. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, home test for pregnancy "Risk Factors" in the company's third quarter 2008 10-Q. Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients.
For more information about these ongoing Phase III studies, please visit /, search term boceprevir. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around dna home testing kits the world. SVR 12 is defined as undetectable HCV-RNA in plasma at 12 weeks after the end of treatment. Important Safety Information Regarding U.S. Injection site pain was reported in 2% of patients receiving PEGINTRON. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group. In many, but not all cases, these disorders motive after stopping PEGINTRON and/or INTRON A therapy.
Forward-looking statements relate to expectations or forecasts of future events. The two studies are expected to enroll a total of more than 1,400 patients at U.S. The protocol specified primary efficacy endpoint of the HCV SPRINT-1 study is SVR as defined above.
Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL. Prescribing information and the Medication Guide for PEGINTRON at /. The HCV SPRINT-1 study was conducted at sites across the United States, Canada and Europe. Kwo P, Lawitz E, McCone J, et al.
The study in treatment-naive patients is known as HCV SPRINT-2 and the study in patients who failed prior treatment is known as HCV RESPOND-2. It is the most com blood-borne infection in America and Europe, and the most com form of liver disease, affecting
.
|
|
